NCT05318469 – A Phase I/II Study Evaluating the Safety and Efficacy of Ivermectin in Combination With Immune Checkpoint Inhibitor in Patients With Metastatic Triple Negative Breast Cancer and HR+/HER2- Metastatic Breast Cancer (2026)

Government Record · Yuan Yuan (Cedars-Sinai Medical Center), lead sponsor; collaborators Agenus Inc. and Gateway for Cancer Research · October 30, 2026

Yuan Yuan (Cedars-Sinai Medical Center), 2026-10-30: Registry record for a single-arm phase I/II trial in metastatic TNBC combining ivermectin with balstilimab or pembrolizumab, started 13 Oct 2023, still recruiting, 34 patients estimated, no results posted.

Ivermectin at the assigned dose administered PO on Days 1-3, 8-10, 15-17 of each 21 day cycle (Days1-3 of each week).

Yuan Yuan (Cedars-Sinai Medical Center), 2026-10-30: Registry record for a single-arm phase I/II trial in metastatic TNBC combining ivermectin with balstilimab or pembrolizumab, started 13 Oct 2023, still recruiting, 34 patients estimated, no results posted. C7 human data. Record fields transcribed from the ClinicalTrials.gov API v2 JSON (the human study page is JS-rendered): overall status RECRUITING, status verified 2026-10, start 2023-10-13, primary completion estimated 2026-10, enrollment 34 (estimated), phases PHASE1/PHASE2, single group, no masking. Interventions: balstilimab 450 mg IV (or pembrolizumab 200 mg IV) day 1 of each 21-day cycle; ivermectin PO days 1-3, 8-10, 15-17 to progression or 2 years. Primary outcomes: RP2D (phase 1) and objective response rate (phase 2). 'hasResults': false – registered, no results posted. Funding: Agenus (maker of balstilimab) is a collaborator; Gateway for Cancer Research also collaborates. This is a combination trial with no ivermectin-alone arm. Study type: regulatory record.